{
    "clinical_study": {
        "@rank": "146229", 
        "arm_group": {
            "arm_group_label": "124I-labeled anti-amyloid mAb 11-1F4", 
            "arm_group_type": "Experimental", 
            "description": "124I-labeled anti-amyloid mAb 11-1F4 will be infused on day 0. Two and 5 days later, PET/CT scans will be performed."
        }, 
        "brief_summary": {
            "textblock": "The purpose of the study is to determine the capability of a radiolabeled amyloid-reactive\n      monoclonal antibody (mAb) to document the presence and distribution of amyloid deposits by\n      PET/CT imaging in patients with AL amyloidosis."
        }, 
        "brief_title": "Radioimmunoimaging of Light Chain (AL) Amyloidosis", 
        "completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "condition": "AL Amyloidosis", 
        "condition_browse": {
            "mesh_term": "Amyloidosis"
        }, 
        "detailed_description": {
            "textblock": "To be eligible for this study, patients must have a confirmed diagnosis of AL amyloidosis\n      without significant cardiac (New York Heart Association class IV) disease and not be on\n      kidney dialysis. Additionally, after testing, their blood must not contain antibodies to\n      mouse proteins. The study requires an intravenous infusion, given over 10 minutes, of the\n      radiolabeled antibody, followed 48 hours later by a PET/CT scan. A repeat scan is done 5\n      days after infusion of the antibody. A 5-ml blood specimen needs to be furnished 4 and 8\n      weeks after the antibody infusion."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients with a confirmed diagnosis of AL amyloidosis.\n\n        Exclusion Criteria:\n\n          -  New York Heart Association class IV\n\n          -  On renal dialysis\n\n          -  Serum antibodies to mouse protein"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "90 Years", 
            "minimum_age": "21 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 13, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01815086", 
            "org_study_id": "IND 100472", 
            "secondary_id": "1 RO1 FD003420-01A1"
        }, 
        "intervention": {
            "arm_group_label": "124I-labeled anti-amyloid mAb 11-1F4", 
            "description": "Single infusion of 124I-labeled anti-amyloid mAb 11-1F4: 2 mCi (1 mg)", 
            "intervention_name": "Single infusion of 124I-labeled anti-amyloid mAb 11-1F4: 2 mCi (1 mg)", 
            "intervention_type": "Biological"
        }, 
        "intervention_browse": {
            "mesh_term": "Antibodies, Monoclonal"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Radioimmunoimaging", 
            "AL Amyloidosis", 
            "PET/CT"
        ], 
        "lastchanged_date": "September 17, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Knoxville", 
                    "country": "United States", 
                    "state": "Tennessee", 
                    "zip": "37920"
                }, 
                "name": "University of Tennessee Medical Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Radioimmunoimaging (PET/CT) of Patients With AL Amyloidosis Using the 124I-Labeled Amyloid-Reactive Monoclonal Antibody (mAb) Murine (Mu) 11-F4", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "PET/CT images will be taken 2 and 5 days post-radiolabeled antibody infusion to evaluate if there is organ/tissue uptake (greater than blood pool) and to determine if the presence of radiolabeled antibody correlates with clinically proven amyloid deposition.", 
            "measure": "Determination of the capability of a radiolabeled amyloid-reactive monoclonal antibody (mAb) to document the presence and distribution of amyloid deposits by  PET/CT in up to 30 patients with AL amyloidosis.", 
            "safety_issue": "Yes", 
            "time_frame": "Five days post PET/CT scan"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01815086"
        }, 
        "responsible_party": {
            "investigator_affiliation": "FDA Office of Orphan Products Development", 
            "investigator_full_name": "Alan Solomon", 
            "investigator_title": "Professor of Mediciine; Head, Human Immunology & Cancer Program", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "University of Tennessee", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Tennessee", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2008", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}